MedTrace Logo

Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

NCT05745623 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-09-11

No results posted yet for this study

Summary

A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors

Conditions

  • Advanced Solid Tumors Harboring NTRK Fusion
  • Primary Central Nervous System Tumors Harboring NTRK Fusion

Interventions

DRUG

ICP-723

ICP-723 tablet administered orally，once a day，for every 28 days as one cycle

Sponsors & Collaborators

  • Beijing InnoCare Pharma Tech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ruihua Xu · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-27
Primary Completion
2027-12-25
Completion
2028-12-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05745623 on ClinicalTrials.gov